HHC
SAGE

Hutchin Hill Capital’s Sage Therapeutics SAGE Stock Holding History

Hutchin Hill Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-10,000
Closed -$315K – 679
2014
Q3 		$315K Buy
+10,000
New +$290K 0.01% 514

Other funds holding SAGE

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Hutchin Hill Capital's SAGE Position: Q4 2014 in Review

Hutchin Hill Capital sold out of Sage Therapeutics (SAGE) in Q4 2014, closing a stake of 10,000 shares — an estimated $315K sold.

Hutchin Hill Capital first reported a position in SAGE in Q3 2014 and held it in 1 quarter. The position peaked at $315K in Q3 2014. 73 funds tracked by Wall St. Rank hold SAGE as of Q4 2014.

  • Hutchin Hill Capital reported no remaining Sage Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Hutchin Hill Capital sold 10,000 Sage Therapeutics shares in Q4 2014, an estimated $315K.
  • Hutchin Hill Capital first reported a position in Sage Therapeutics in Q3 2014 and held it in 1 quarter.
  • Hutchin Hill Capital's Sage Therapeutics position peaked at $315K in Q3 2014.
  • 73 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2014.

Based on Hutchin Hill Capital's 13F filing for Q4 2014, filed 17 Feb 2015.